Item submitted by Isis Innovation
The following technologies have recently been added to the Isis Innovation portfolio.
Tuberculosis (TB) Vaccine
Research at the University of Oxford has resulted in the development of the leading vaccine in clinical trials for the prevention of tuberculosis (TB).
The Oxford vaccine consists of a non-replicating viral vector expressing a TB antigen, which is able to stimulate a powerful cellular immune response in both preclinical and clinical studies. The vaccine is currently in Phase II clinical trials to demonstrate safety and immunogenicity in different patient populations
New Fluorination Process
Processes for the production of fluorinated compounds as useful building blocks in the development of candidate pharmaceutical drugs, agrochemicals or electronic materials such as liquid crystals and photoresists.
Therapeutic Tolerogenic Antibodies
A new platform technology which has the potential to alleviate tolerance issues associated with immuno or peptide based therapeutic drugs.
Modified Carbohydrate Processing Enzymes
Methods for modifying carbohydrate processing enzymes to increase activity and specificity. The technology has broad application including the creation of pure glycoproteins as potential therapeutics.
Antibodies to Sodium Channel Isoforms
Polyclonal antibodies have been generated which target for the first time the external pore region of different sodium channel isoforms. These will open the door for research into the function of these isoforms in living cells, and potentially new therapeutics for conditions where blockage of sodium channels is desirable.
The following technologies have recently been added to the Isis Innovation portfolio.
Tuberculosis (TB) Vaccine
Research at the University of Oxford has resulted in the development of the leading vaccine in clinical trials for the prevention of tuberculosis (TB).
The Oxford vaccine consists of a non-replicating viral vector expressing a TB antigen, which is able to stimulate a powerful cellular immune response in both preclinical and clinical studies. The vaccine is currently in Phase II clinical trials to demonstrate safety and immunogenicity in different patient populations
New Fluorination Process
Processes for the production of fluorinated compounds as useful building blocks in the development of candidate pharmaceutical drugs, agrochemicals or electronic materials such as liquid crystals and photoresists.
Therapeutic Tolerogenic Antibodies
A new platform technology which has the potential to alleviate tolerance issues associated with immuno or peptide based therapeutic drugs.
Modified Carbohydrate Processing Enzymes
Methods for modifying carbohydrate processing enzymes to increase activity and specificity. The technology has broad application including the creation of pure glycoproteins as potential therapeutics.
Antibodies to Sodium Channel Isoforms
Polyclonal antibodies have been generated which target for the first time the external pore region of different sodium channel isoforms. These will open the door for research into the function of these isoforms in living cells, and potentially new therapeutics for conditions where blockage of sodium channels is desirable.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
